周五， 中慧生物-B 老虎暗盘开盘暴涨，截至发稿涨幅超160%，不计手续费，每手赚超4200港币。中慧生物-B公开发售录得超4000倍超额认购，成为今年港股生物科技新股超购王。VanCapital、InfiniCapital等全球知名长线基金积极参与。
公司原计划8月8日挂牌上市，不过受香港当地“黑色暴雨”恶劣天气影响，上市时间推迟至8月11日。
公司简介
中慧生物科技股份有限公司是一家专注于人用疫苗研发、生产和销售的内地企业，产品涵盖狂犬病疫苗、乙肝疫苗等，瞄准全球预防传染病市场需求。
目前，中慧生物有两种核心产品，即四价流感病毒亚单位疫苗（商品名“慧尔康欣”）及在研冻干人用狂犬病疫苗（其使用人二倍体细胞开发，具有良好的安全性）；及其他11种在研疫苗，涵盖对疫苗接种有庞大需求的多个疾病领域。
发行情况
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
